Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 3/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | PLK4 | O00444 | 1/20 | 0.33 |
| ▸ | PAK4 | O96013 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7486559 | 0.76 | MAPK1 (0.32) | — | |
| SCHEMBL53863 | 0.63 | PLK4 (0.47) | NOS1DYRK1APLK4PAK4PDE2A | |
| SCHEMBL838113 | 0.63 | — | — | |
| SCHEMBL2266999 | 0.60 | PLK4 (0.45) | NOS1DYRK1APLK4PAK4PDE2A | |
| SCHEMBL560806 | 0.60 | RET (0.52) | NOS1PLK4PAK4PDE2A | |
| SCHEMBL61883 | 0.60 | PLK4 (0.53) | PLK4PAK4PDE2A | |
| SCHEMBL291015 | 0.60 | — | — | |
| SCHEMBL4741666 | 0.60 | MAOA (0.43) | NOS1 | |
| SCHEMBL130504 | 0.58 | PLK4 (0.57) | PLK4PAK4PDE2A | |
| SCHEMBL29480802 | 0.57 | NOS1 (0.47) | NOS1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063064-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2011-11-22 | — | — | US | disclosed |
| EP-2057125-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-03-30 | — | — | EP | disclosed |
| US-20110059975-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | KENNEDY-SMITH JOSHUA | 2011-03-10 | — | — | US | disclosed |
| US-7713974-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2010-05-11 | — | — | US | disclosed |
| US-20080045511-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045511-A1 | Non-nucleoside reverse transcriptase inhibitors | ADORA2B, ADORA1, ADORA3 | NOS1 349/4885DYRK1A 3850/4885PLK4 3006/4885 |
| US-20110059975-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | RPIA, ADORA2B, NQO2 | NOS1 452/4885DYRK1A 3718/4885PLK4 3083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.